Farampator

From Wikipedia, the free encyclopedia
  (Redirected from CX-691)
Jump to navigation Jump to search
Farampator
Farampator.svg
Farampator ball-and-stick model.png
Clinical data
Synonyms CX-691; ORG-24448
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
Formula C12H13N3O2
Molar mass 231.25052 g/mol
3D model (JSmol)
 NoYesY (what is this?)  (verify)

Farampator (developmental code names CX-691, ORG-24448, SCH-900460) is an ampakine drug. It was developed by Cortex Pharmaceuticals, and licensed to Organon BioSciences for commercial development. Following the purchase of Organon by Schering-Plough in 2007, the development license to farampator was transferred. The development of farampator was eventually terminated, reportedly due to concerns about cardiac toxicity.[1][2]

Farampator has been investigated for its effect on AMPA receptors and researched for potential use in the treatment of schizophrenia and Alzheimer's Disease. It was found to improve short-term memory, but impaired episodic memory. It produced side effects such as headache, somnolence and nausea. Subjects reporting side effects had significantly higher plasma levels of farampator than subjects without.[citation needed] Additional analyses revealed that in the farampator condition the group without side effects showed a significantly superior memory performance relative to the group with side effects. [3]

See also[edit]

References[edit]

  1. ^ http://adisinsight.springer.com/drugs/800012259
  2. ^ Froestl W, Muhs A, Pfeifer A (2012). "Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors". J. Alzheimers Dis. 32 (4): 793–887. doi:10.3233/JAD-2012-121186. PMID 22886028. 
  3. ^ Wezenberg E, Verkes RJ, Ruigt GS, Hulstijn W, Sabbe BG. Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers. Neuropsychopharmacology. 2007 Jun;32(6):1272-83. doi:10.1038/sj.npp.1301257 PMID 17119538